Lv1
50 积分 2024-11-20 加入
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy
4天前
已完结
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
5天前
已完结
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study
6天前
已完结
Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
10天前
已完结
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
11天前
已完结
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
18天前
已完结
三阴性乳腺癌精准治疗研究的新进展与未来展望
25天前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
26天前
已完结
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
28天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
28天前
已完结
皖公网安备34019202002308
